Mechanism
Pancreatic β-cell effects
GLP-1 and GIP both enhance the pancreas's ability to release insulin when blood glucose rises. Because the effect is glucose-dependent, it does not typically cause hypoglycaemia on its own — though combined use with insulin or sulfonylureas changes that risk.
Plain-English explanation
GLP-1 and GIP both enhance the pancreas's ability to release insulin when blood glucose rises. Because the effect is glucose-dependent, it does not typically cause hypoglycaemia on its own — though combined use with insulin or sulfonylureas changes that risk.
Research-level explanation
Well-characterised across decades of incretin pharmacology. Outcome-trial data confirm clinically meaningful glycaemic benefit at licensed doses.
Common misconceptions
| Common claim | More accurate framing |
|---|---|
| GLP-1 RAs always cause hypoglycaemia. | On their own at licensed doses, GLP-1 RAs produce glucose-dependent insulin release with low hypoglycaemia risk. Risk rises when combined with insulin or sulfonylureas. |
Safety relevance
Hypoglycaemia risk when combined with sulfonylureas or insulin; pancreatitis signal monitored across the class.
- β-cell preservation hypotheses from animal models have not been definitively confirmed in long-term human data.
Related peptide profiles
Related trials
Related conditions
Related safety signals
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationFrías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med 2021.
- Peer-reviewed publicationMarso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — Scientific guidelines
EMA scientific guidelines covering pharmacodynamic mechanisms
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of mechanism profiles on this site